Challenges in Developing Biosimilars

The biosimilars market is set to expand over the next decade and beyond as a result of two major factors: the impending patent expires on blockbuster biologics and the financial crisis that is driving payers to push for wider adoption of biosimilars to manage the escalating costs of healthcare. Although many companies are keen on getting a share in the biosimilars market given its promising outlook, bringing these complex molecules from bench to launch can be a challenge, not just during the development stage but also in terms of the manufacturing process involved. 

  • Equivalence of complex drug products
  • Biosimilar monoclonal antibodies
  • Economic aspect towards biosimilars
  • Advertising, promotion and labeling essentials
  • Drug Safety essentials
  • Early clinical development essentials
  • Late clinical development essentials
  • Current concepts of drugs and biologics
  • Unique considerations for biologics
  • Comparability for Biologics

Related Conference of Challenges in Developing Biosimilars

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4thInternational Conference on Drug Discovery, Designing Chemistry and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Challenges in Developing Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in